Hayat Pharmaceutical Industries Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Maher Mohammed Al Kurdi
Chief executive officer
د.أ434.3k
Total compensation
| CEO salary percentage | 63.6% |
| CEO tenure | 22.9yrs |
| CEO ownership | 7.8% |
| Management average tenure | 7.7yrs |
| Board average tenure | no data |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | د.أ3m |
| Jun 30 2024 | n/a | n/a | د.أ3m |
| Mar 31 2024 | n/a | n/a | د.أ2m |
| Dec 31 2023 | د.أ434k | د.أ276k | د.أ2m |
| Sep 30 2023 | n/a | n/a | د.أ2m |
| Jun 30 2023 | n/a | n/a | د.أ2m |
| Mar 31 2023 | n/a | n/a | د.أ3m |
| Dec 31 2022 | د.أ434k | د.أ217k | د.أ4m |
| Sep 30 2022 | n/a | n/a | د.أ3m |
| Jun 30 2022 | n/a | n/a | د.أ3m |
| Mar 31 2022 | n/a | n/a | د.أ2m |
| Dec 31 2021 | د.أ427k | د.أ207k | د.أ4m |
Compensation vs Market: Maher Mohammed's total compensation ($USD611.92K) is above average for companies of similar size in the JO market ($USD160.24K).
Compensation vs Earnings: Maher Mohammed's compensation has been consistent with company performance over the past year.
CEO
Maher Mohammed Al Kurdi (66 yo)
22.9yrs
Tenure
د.أ434,338
Compensation
Dr. Maher Mohammed Ali Al Kurdi is Founder and Non-Independent Executive Vice-Chairman of Hayat Pharmaceutical Industries Co. PLC and has been its Managing Director since February 17, 2002. Dr. Al Kurdi Jo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 22.9yrs | د.أ434.34k | 7.82% JOD 1.9m | |
| Deputy Managing Director of Institutional Development | 3.6yrs | د.أ180.03k | no data | |
| Chief Financial Officer | 7.7yrs | no data | no data |
7.7yrs
Average Tenure
Experienced Management: HPIC's management team is seasoned and experienced (7.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 22:35 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hayat Pharmaceutical Industries Co. PLC is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|